CTSO Cytosorbents Corp
Price (delayed)
$1.03
Market cap
$56.06M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.53
Enterprise value
$67.47M
CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 66 countries around the
Highlights
The quick ratio has soared by 75% QoQ and by 4.3% YoY
The gross profit rose by 15% year-on-year and by 2.1% since the previous quarter
The debt has surged by 53% since the previous quarter and by 46% year-on-year
The equity has declined by 31% year-on-year and by 12% since the previous quarter
Key stats
What are the main financial stats of CTSO
Market
Valuations
Earnings
Shares outstanding
54.43M
Market cap
$56.06M
Enterprise value
$67.47M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.34
Price to sales (P/S)
1.51
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.82
Revenue
$37.16M
EBIT
-$26.07M
EBITDA
-$23.93M
Free cash flow
-$21.54M
Per share
Balance sheet
Liquidity
EPS
-$0.53
Free cash flow per share
-$0.4
Book value per share
$0.31
Revenue per share
$0.68
TBVPS
$0.98
Total assets
$53.43M
Total liabilities
$36.69M
Debt
$26.35M
Equity
$16.74M
Working capital
$11.62M
Debt to equity
1.57
Current ratio
2.12
Quick ratio
2.2
Net debt/EBITDA
-0.48
Margins
Efficiency
Dividend
EBITDA margin
-64.4%
Gross margin
64.6%
Net margin
-68.7%
Operating margin
-67.4%
Return on assets
-50.7%
Return on equity
-131.8%
Return on invested capital
-58%
Return on capital employed
-60.5%
Return on sales
-70.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CTSO stock price
How has the Cytosorbents stock price performed over time
Intraday
0.98%
1 week
-1.9%
1 month
1.98%
1 year
-56.9%
YTD
-7.21%
QTD
46.51%
Financial performance
How have Cytosorbents's revenue and profit performed over time
Revenue
$37.16M
Gross profit
$23.99M
Operating income
-$25.04M
Net income
-$25.53M
Gross margin
64.6%
Net margin
-68.7%
Cytosorbents's operating margin has increased by 18% YoY and by 12% QoQ
CTSO's operating income is up by 16% year-on-year and by 11% since the previous quarter
The gross profit rose by 15% year-on-year and by 2.1% since the previous quarter
The gross margin is up by 13% YoY
Growth
What is Cytosorbents's growth rate over time
Valuation
What is Cytosorbents stock price valuation
P/E
N/A
P/B
3.34
P/S
1.51
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.82
CTSO's EPS is up by 12% YoY and by 10% from the previous quarter
CTSO's P/B is 54% lower than its 5-year quarterly average of 7.3 but 15% higher than its last 4 quarters average of 2.9
The equity has declined by 31% year-on-year and by 12% since the previous quarter
The stock's price to sales (P/S) is 70% less than its 5-year quarterly average of 5.1
Cytosorbents's revenue has increased by 2.2% YoY
Efficiency
How efficient is Cytosorbents business performance
The ROE has plunged by 59% YoY
The ROA has decreased by 13% YoY but it has increased by 8% QoQ
The ROIC has grown by 13% from the previous quarter and by 6% YoY
CTSO's ROS is up by 9% from the previous quarter and by 7% YoY
Dividends
What is CTSO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CTSO.
Financial health
How did Cytosorbents financials performed over time
The company's total assets is 46% higher than its total liabilities
The quick ratio has soared by 75% QoQ and by 4.3% YoY
CTSO's current ratio is up by 42% since the previous quarter but it is down by 7% year-on-year
The debt is 57% greater than the equity
The debt to equity has soared by 109% year-on-year and by 73% since the previous quarter
The debt has surged by 53% since the previous quarter and by 46% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.